The DOI matches its Crossref record.
Cellular and behavioural effects of the adenosine A2a receptor antagonist KW‐6002 in a rat model of l‐DOPA‐induced dyskinesia
Open accessAbstract
We have examined the ability of KW‐6002, an adenosine A 2a antagonist, to modulate the dyskinetic effects of l‐DOPA in 6‐hydroxydopamine‐lesioned rats. In animals rendered dyskinetic by a previous course of l‐DOPA treatment, KW‐6002 did not elicit any abnormal involuntary movements on its own, but failed to reduce the severity of dyskinesia when coadministered with l‐DOPA. A second experiment was undertaken in order to study the effects of KW‐6002 in l‐DOPA‐naive rats. Thirty‐five animals were allotted to four groups to receive a 21‐day treatment with: (i) KW‐6002 (10 mg/kg/day); (ii) l‐DOPA (6 mg/kg/day) i.p.; (iii) KW‐6002 plus l‐DOPA (same doses as above) or (iv) vehicle. Chronic treatment with KW‐6002‐only produced a significant relief of motor disability in the rotarod test in the absence of any abnormal involuntary movements. Combined treatment with l‐DOPA and KW‐6002 improved rotarod performance to a significantly higher degree than did each of the two drugs alone. However, this combined treatment induced dyskinesia to about the same degree as did l‐DOPA alone. In situ hybridization histochemistry showed that KW‐6002 treatment alone caused an approximately 20% reduction in the striatal levels of preproenkephalin mRNA, whereas neither the coadministration of KW‐6002 and l‐DOPA nor l‐DOPA alone significantly altered the expression of this transcript in the dopamine‐denervated striatum. Either alone or in combination with l‐DOPA, KW‐6002 did not have any modulatory effect on prodynorphin mRNA expression or FosB/ΔFosB‐like immunoreactivity in the dopamine‐denervated striatum. These results show that monotreatment with an adenosine A 2a receptor antagonist can relieve motor disability without inducing behavioural and cellular signs of dyskinesia in rats with 6‐hydroxydopamine lesions. Cotreatment with KW‐6002 and l‐DOPA potentiates the therapeutic effect but not the dyskinesiogenic potential of the latter drug.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Duty, S., & Jenner, P. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01426.x · Cited by 753
Fredholm, B. B., Chen, J.-F., Cunha, R. A., Svenningsson, P., & Vaugeois, J.-M. (2005) · International Review of Neurobiology · doi:10.1016/s0074-7742(05)63007-3 · Cited by 692
Caffeine as a psychomotor stimulant: mechanism of action
Fisone, G., Borgkvist, A., & Usiello, A. (2004) · Cellular and Molecular Life Sciences (CMLS) · doi:10.1007/s00018-003-3269-3 · Cited by 538
Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease
Bastide, M. F., Meissner, W. G., Picconi, B., Fasano, S., Fernagut, P.-O., Feyder, M., Francardo, V., Alcacer, C., Ding, Y., Brambilla, R., et al. (2015) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.07.002 · Cited by 475
Targeting adenosine A2A receptors in Parkinson's disease
Schwarzschild, M. A., Agnati, L., Fuxe, K., Chen, J.-F., & Morelli, M. (2006) · Trends in Neurosciences · doi:10.1016/j.tins.2006.09.004 · Cited by 433
Metadata
- Authors
- Lundblad, M., Vaudano, E., & Cenci, M. A.
- Venue
- Journal of Neurochemistry
- Publisher
- Wiley
- Published
- 2003-02-28
- Volume
- 84
- Issue
- 6
- Pages
- 1398-1410
- ISSN
- 0022-3042 (ISSN-L)
- 1471-4159
- OpenAlex
- W2131371182
- Cited by
- 168
- References
- 0
- FWCI
- 6.21
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cellular and behavioural effects of the adenosine A2a receptor antagonist KW‐6002 in a rat model of l‐DOPA‐induced dyskinesia. https://app.cochat.ai/papers/10.1046/j.1471-4159.2003.01632.x
- The paper
- Lundblad, M., Vaudano, E., & Cenci, M. A. (2003). Cellular and behavioural effects of the adenosine A2a receptor antagonist KW‐6002 in a rat model of l‐DOPA‐induced dyskinesia. Journal of Neurochemistry. https://doi.org/10.1046/j.1471-4159.2003.01632.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.